FDA Clears Apollo Endosurgery’s SuMO Endoscopic Tissue Access and Resection System

The FDA cleared Apollo Endosurgery’s SuMO endoscopic tissue access and resection system, which allows surgeons to remove large, flat precancerous gastrointestinal lesions and polyps during endoscopy procedures without leaving scars, according to a news release.

Advertisement

The SuMO system, which stands for Sub-Mucosal Operation, was developed through a partnership between Apollo Endosurgery and the Mayo Clinic, Johns Hopkins University, the Medical University of South Carolina and the University of Texas Medical Branch. The system includes flexible injection needles, balloons and cutting tools to help the surgeon tunnel underneath the lesion and resect, seal off and remove the unwanted tissue through a traditional endoscope. Preclinical proof-of-concept studies showed the device to be effective in the removal of gastrointestinal tissue up to 7 cm in diameter.

Related Articles on Medical Devices:
St. Jude Medical Plans to Double its Location in Plymouth, Minnesota
FDA Clears Intuitive Surgical Vessel Sealer for da Vinci Surgical System
Top 3 Reasons Behind the Drug Shortage Nightmare

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.